As a group, equities analysts expect that Mirati Therapeutics, Inc. will post -13.5 earnings per share for the current year.

Source: https://www.americanbankingnews.com/2023/01/26/bank-julius-baer-co-ltd-zurich-buys-8966-shares-of-mirati-therapeutics-inc-nasdaqmrtx-2.html

Finally, Great West Life Assurance Co. Can purchased a new stake in Mirati Therapeutics in the third quarter worth approximately $145,000.

Source: https://www.etfdailynews.com/2023/05/20/russell-investments-group-ltd-buys-33186-shares-of-mirati-therapeutics-inc-nasdaqmrtx/

MetLife Investment Management LLC purchased a new position in shares of Mirati Therapeutics in the 1st quarter valued at about $197,000.

Source: https://www.etfdailynews.com/2023/07/02/mirati-therapeutics-inc-nasdaqmrtx-shares-bought-by-assenagon-asset-management-s-a/

Mirati Therapeutics shares are currently trading at above $42, and are down by almost 4% year-to-date, bringing their one-year return to -46%.

Source: https://247wallst.com/investing/2023/03/06/these-are-the-top-10-holdings-of-david-kim/

Quadrant Capital Group LLC boosted its position in shares of Mirati Therapeutics by 161.6% during the 2nd quarter.

Source: https://www.etfdailynews.com/2023/02/19/california-public-employees-retirement-system-has-6-47-million-position-in-mirati-therapeutics-inc-nasdaqmrtx/

Quadrant Capital Group LLC raised its stake in Mirati Therapeutics by 161.6% in the second quarter.

Source: https://www.americanbankingnews.com/2023/03/04/blueshift-asset-management-llc-takes-260000-position-in-mirati-therapeutics-inc-nasdaqmrtx.html